We used genome-wide DNA methylation data from CATNON trial samples and compared profiles of IDH1R132H mutated tumours (n = 369) to those harbouring other “non-R132H” IDH1 and IDH2 hotspot mutations (n = 69). This evidence concerns the gene IDH2 and neoplasm.